Latest News

The poster we presented at the Alzheimer’s Association International Conference is now available on the ETAP-Lab website; it’s all about our innovative in vitro and in vivo models of Alzheimer's disease, which are based on the use of human A-Beta 1-42 oligomers. The poster focuses on the main results of the characterisation of the model in the aged mouse. This reproducible and translational model is a new tool for the evaluation of compounds targeting the early stages of Alzheimer's disease. We are

ETAP-Lab will present its new Alzheimer's model in the aged mouse at the Alzheimer's Association International Conference, to be held in Denver (USA) from 26 to 30 July 2021. Our expert, Dr. Ahmad Allouche, will be there to answer your questions about our in vitro and in vivo models of Alzheimer's disease, based on the use of human A-Beta 1-42 oligomers. Our poster entitled "New Alzheimer models for drug screening, based on improved human amyloid beta (1-42) oligomer preparations" (number #54152), presents

Low non-cytotoxic doses of ETAP-Lab’s human amyloid beta 1-42 oligomers (AβO) are disrupting functional neuronal network activity in NETRI’s microfluidic device coupled with MEA. This result is an important milestone towards a more relevant and physiological model of Alzheimer’s disease for drug screening and mechanistic studies. For more information download the Application Note #alzheimer #DrugScreening #microfluidics #neuroscience

Did you know that ETAP-Lab has been working in the field of probiotics for more than 15 years, being pioneer in the preclinical study of the gut-brain axis? ETAP-Lab will share its experiences about probiotics testing in preclinical models during the 19th Meet&Match event focused on microbiome, a virtual event scheduled the 1st of July. Dr Jean-François Bisson will talk about: “Assessing beneficial effects of probiotics in small animal models: ETAP-Lab ‘s experience” during Session II at 11h55. This event is co-organized by BioValley France

ETAP-Lab will be attending BIODigital as part of the BusinessFrance virtual French pavilion (from 10 to 18 June). Our experts Dr. Jean-François Bisson (VP) and Dr. Nicolas Violle (CEO) will be there to introduce you to the laboratory's activities in preclinical Dermatology, NutritionHealth and Neurology, with Stroke, Alzheimer’s and Parkinson’s diseases. Please feel free to contact us to schedule a video conference. We’re hoping to meet you soon!

Intracerebral administration of AB1-42 (AβO) oligomers disrupts synaptic function and increases cell death in brain tissue in aged mice. As announced a few weeks ago, we evaluated the effects of AβO on synaptic function and cell survival. Quantification of protein expression in the hippocampus 18 days after intracerebral administration showed disruption to synaptic function (PSD-95) and apoptotic signalling in brain tissue. Figure 1: Graphical representation of PSD-95 expression and Bax/Bcl-2 ratio in the hippocampus, 18 days after AβO

As announced a few weeks ago, we tested the effects of donepezil (DPZ) in our Alzheimer's disease model, induced by the administration of beta-amyloid oligomers 1-42. We have shown that memory disorders induced by A-Beta oligomers could be significantly reduced by this symptomatic treatment of Alzheimer's disease. This strengthens the pharmacological validity of our model. In addition, we have once again shown the reproducibility of our model. We have shown that the deleterious effects on memory induced by the administration of A-beta

The toxicity of our beta-amyloid peptide oligomers is confirmed in vivo in elderly mice After several months’ development, several replicated studies show that oligomers of A-beta peptides (whose neurotoxicity in vitro is well documented), induce cognitive deficits in object recognition test and Morris watermaze in the weeks following intracerebroventricular injection in 18-month-old mice. We have shown that the administration of A-beta 1-42 oligomers leads to significant memory impairment in the object recognition test: while animals in the vehicle group show a significant

All of us here at ETAP-Lab and STROK@LLIANCE hope all of you are in good health, and wish you every success in all your endeavours, in 2021 and beyond. As we approach the end of this year unlike any other, we wanted to let you know how ETAP-Lab has managed - and share our plans for 2021 with you. During the health crisis Despite two periods of lockdown ETAP-Lab’s activity has not diminished - quite the opposite, in fact! Having ground to an

In partnership with Lallemand Health Solutions, Aspen Farmacêutica is bringing the first psychobiotic formulation for the gut-brain axis to the Brazilian market. The two finished products are Probid and Probians and contain two strains of probiotics for which the following claims are now approved: Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 may contribute to the reduction of feelings of anxiety in healthy individuals. Lactobacillus helveticus Rosell-52 and Bifidobacterium longum Rosell-175 contribute to the reduction of gastrointestinal complications (such as abdominal pain and nausea/vomiting) brought on by light